Quarterly Result5 Feb 2026, 02:25 pm
Alembic Pharmaceuticals Reports 11% Revenue Growth in Q3 FY26
AI Summary
Alembic Pharmaceuticals Limited reported its consolidated financial results for the third quarter and nine months ended 31st December 2025. The company's revenue from operations increased by 11% to Rs.1,876 Cr, EBITDA increased by 14% to Rs. 308 Cr, and Profit Before Exceptional Items and Tax increased by 15% to Rs 205 Cr. The company also invested around 9% of revenue in R&D to build a robust pipeline for future growth. The integration of Utility Therapeutics progressed well, and the company is working towards launch of Pivya™ in quarter 4.
Key Highlights
- Revenue from operations increased by 11% to Rs.1,876 Cr.
- EBITDA increased by 14% to Rs. 308 Cr.
- Profit Before Exceptional Items and Tax increased by 15% to Rs 205 Cr.
- Invested around 9% of revenue in R&D.
- Progress in the integration of Utility Therapeutics.